Physician profile
Chitra Nathan
NPI 1013119288
$3,684.20
in general payments reported to CMS, 2019-2025
29 companies · $1,049 in 2025
The $1,049 reported for 2025 was more than what 79% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $530 · 2020: $136 · 2021: $296 · 2022: $403 · 2023: $567 · 2024: $703 · 2025: $1,049.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,272 · Education: $47.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,271.83 |
| Education | $47.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $375.39 | 2019-2025 | Farxiga, Lokelma, Evusheld |
| Calliditas Therapeutics US INC. | $316.42 | 2023-2025 | Tarpeyo |
| Horizon Therapeutics Plc | $301.72 | 2019-2023 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $298.77 | 2019-2025 | Jynarque |
| Amgen INC. | $258.47 | 2020-2025 | Krystexxa, Tavneos |
| Mallinckrodt Enterprises LLC | $235.43 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $230.77 | 2021-2025 | |
| Travere Therapeutics, INC. | $216.03 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $152.19 | 2024-2025 | |
| Vifor Pharma, INC. | $135.87 | 2021-2025 | Veltassa |
| Fresenius USA Marketing, INC. | $121.83 | 2019-2025 | Velphoro, Velphoro |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $119.72 | 2019-2025 | |
| Novo Nordisk INC | $111.55 | 2023-2025 | Ozempic, Rybelsus |
| Akebia Therapeutics INC | $105.95 | 2024-2025 | Vafseo, Auryxia |
| Glaxosmithkline, LLC. | $101.03 | 2022-2025 | Benlysta |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $94.56 | 2021-2023 | Rayaldee |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.82 | 2021-2025 | Jardiance |
| Alexion Pharmaceuticals, INC. | $51.24 | 2021-2024 | Ultomiris |
| Apellis Pharmaceuticals, INC. | $50.02 | 2025 | Empaveli |
| Ani Pharmaceuticals, INC. | $44.50 | 2022 | |
| Lilly USA, LLC | $43.57 | 2024-2025 | Jardiance |
| Mallinckrodt Hospital Products INC. | $43.55 | 2022-2025 | Terlivaz |
| Aurinia Pharma U.S., INC. | $35.56 | 2022-2025 | Lupkynis |
| Ultragenyx Pharmaceutical INC. | $31.50 | 2019-2023 | |
| Ardelyx, INC. | $28.98 | 2024 | Ibsrela |
| Nuwellis, INC. | $27.06 | 2022 | |
| Kyowa Kirin, INC. | $24.60 | 2025 | |
| Scpharmaceuticals INC. | $19.88 | 2025 | |
| Genzyme Corporation | $18.22 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chitra Nathan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.